FDA Issues Complete Response Letter for Zynyz in NSCLC Due to Manufacturing Site Issues
Summary
Incyte received an FDA Complete Response Letter for Zynyz in NSCLC, citing issues at a third-party manufacturing facility, not the drug's efficacy or safety.
Key Events
-
FDA Issues Complete Response Letter
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for Zynyz (retifanlimab) for metastatic non-small cell lung cancer (NSCLC).
-
Manufacturing Facility Cited
The CRL was solely due to inspection findings at Catalent Indiana, LLC, a third-party fill-finish facility, and not related to Zynyz's efficacy or safety data.
-
Company Plans Resubmission
Incyte is collaborating with the FDA and Catalent Indiana to address the issues and support a potential sBLA resubmission.
Analysis
Incyte received a Complete Response Letter (CRL) from the FDA for its supplemental Biologics License Application (sBLA) for Zynyz (retifanlimab) in metastatic non-small cell lung cancer (NSCLC). This is a setback as it delays potential market entry for this indication. However, the CRL was solely due to inspection findings at a third-party fill-finish facility (Catalent Indiana) and did not cite concerns regarding Zynyz's efficacy or safety data. The company is actively working with the FDA and Catalent Indiana to resolve the issues and plans for a resubmission, suggesting the delay may be temporary.
At the time of this filing, INCY was trading at $95.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.1B. The 52-week trading range was $53.56 to $112.29. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.